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Abstract
Prostaglandin H1 (PGH1) is the cyclo-oxygenase metabolite of dihomo-c-linolenic acid (DGLA) and the precursor for the 1-
series of prostaglandins which are often viewed as ‘‘anti-inflammatory’’. Herein we present evidence that PGH1 is a potent
activator of the pro-inflammatory PGD2 receptor CRTH2, an attractive therapeutic target to treat allergic diseases such as
asthma and atopic dermatitis. Non-invasive, real time dynamic mass redistribution analysis of living human CRTH2
transfectants and Ca
2+ flux studies reveal that PGH1 activates CRTH2 as PGH2, PGD2 or PGD1 do. The PGH1 precursor DGLA
and the other PGH1 metabolites did not display such effect. PGH1 specifically internalizes CRTH2 in stable CRTH2
transfectants as assessed by antibody feeding assays. Physiological relevance of CRTH2 ligation by PGH1 is demonstrated in
several primary human hematopoietic lineages, which endogenously express CRTH2: PGH1 mediates migration of and Ca
2+
flux in Th2 lymphocytes, shape change of eosinophils, and their adhesion to human pulmonary microvascular endothelial
cells under physiological flow conditions. All these effects are abrogated in the presence of the CRTH2 specific antagonist
TM30089. Together, our results identify PGH1 as an important lipid intermediate and novel CRTH2 agonist which may
trigger CRTH2 activation in vivo in the absence of functional prostaglandin D synthase.
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Introduction
The prostaglandin D2 (PGD2) receptor CRTH2 (chemoattrac-
tant receptor homologous molecule expressed on T helper type 2
(Th2) cells) appears to play a pivotal role in allergic diseases by
influencing migration of inflammatory cells such as eosinophils,
basophils and Th2 cells [1–8]. Pharmacological inhibition of
CRTH2 is associated with a reduction in airway inflammation and
decreased levels of mucus, Th2 cytokines and immunoglobulin E
[9–15]. The central role played by CRTH2 in orchestrating
inflammatory responses suggests that antagonism of this receptor
might represent an attractive strategy to combat allergic diseases.
A hallmark of CRTH2 is that it is not exclusively activated by
PGD2, but responds to a rather broad spectrum of endogenous
ligands. Among those are the PGD2 metabolites 13,14-dihydro-
15-keto-PGD2, D
12-PGD2, PGJ2, 15-deoxy-D
12,14-PGJ2, and D
12-
PGJ2 [16–20], but interestingly also prostanoids generated
independently of PGD synthase activity such as the thromboxane
metabolite, 11-dehydro-TXB2 [21], and the PGF synthase-
dependent, PGF2a [20]. Activation of CRTH2 by prostanoids
generated independently of the PGD synthase allows for the
possibility of CRTH2 signaling in vivo in the absence of PGD2
production and thus reinforces the importance of this receptor in
the orchestration of allergic inflammation.
PGH1 is generated from dihomo-c-linolenic acid (DGLA) by
the action of cyclo-oxygenases (COX) 1 and 2 and represents the
precursor for the 1-series of prostaglandins which have been
mainly viewed as anti-inflammatory [22–27]. PGH2, on the other
hand, is generated from arachidonic acid (AA), the major long
chain polyunsaturated fatty acid in mammalian cell membrane
phospholipids and is a precursor for the 2-series of prostaglandins
[28–30]; see Figure S1 for pathways of prostaglandin production.
Most 2-series prostaglandins have been tested for bioactivity on
CRTH2 and a number of receptor-activating lipids have been
identified [17,3,31]. However, potential modulation of CRTH2
by the 1-series of prostaglandins including their precursors
has not yet been examined. Such investigations appear obligatory
given the recent discovery that 1-series prostaglandins are likely
to be formed in vivo upon ingestion of DGLA [32] and the
widespread promotion of diets enriched with this poly-unsaturated
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asthma [33].
In this study we identify PGH1, the precursor for lipid mediators
with anti-inflammatory potential, as potent and efficacious agonist
for the pro-inflammatory receptor CRTH2. We characterize its
bioactivity using the novel dynamic mass redistribution (DMR)
technology (CorningH EpicH Biosensor) that permits non-invasive,
label-free analysis of receptor signalling in living cells and in real
time [34,35]. We also provide evidence that CRTH2 activation by
PGH1 is detectable in human eosinophils and Th2 cells and leads
to their chemotactic activation, and migration, respectively.
Materials and Methods
Reagents
Tissue culture media and reagents were purchased from
Invitrogen (Karlsruhe, Germany). DGLA, all prostaglandins, and
HQL79 were from Cayman Chemicals (Ann Arbor, MI, USA)
and TM30089 (CAY10471) was synthesized according to
previously published procedures [36]. All other reagents were
obtained from Sigma (Taufkirchen, Germany) unless explicitly
indicated.
Cell culture of CRTH2-HEK cells
Generation of HEK293 cells transfected to stably express
CRTH2 tagged N-terminally with the FLAG-epitope tag
(CRTH2-HEK) was described previously in detail [37]. Native
HEK293 cells were obtained from the American Type Culture
Collection (ATCC). CRTH2-HEK cells were cultivated in
Dulbecco’s modified Eagles medium (DMEM) supplemented with
10% (v/v) fetal bovine serum, 1% sodium pyruvate, 100 U/ml
penicillin, 100 mg/ml streptomycin, and 400 mg/ml G418. Cells
were kept at 37uC in a 5% CO2 atmosphere.
Dynamic mass redistribution (DMR) assay in CRTH2-
HEK293 cells
Dynamic mass redistribution assays were performed on a beta
version of the CorningH EpicH Biosensor (Corning, NY, USA) as
described previously in detail [34,35]. The system detects changes
in the local index of refraction upon stimulus-induced mass
redistribution within the cell monolayer grown in 384-well EpicH
microplates, which are equipped with a resonant wave guide
grating biosensor at the bottom of each well. Cells were seeded at a
density of 18,000 cells/well and cultivated for 20–24 h (37uC, 5%
CO2) on fibronectin-coated EpicH biosensor plates. Cells were
then washed twice with HBSS containing 20 mM HEPES and
kept for 1 h in the EpicH reader at 28uC. The sensor plate was
then scanned to obtain a base-line read prior to applying the
compound solutions.
Calcium ion mobilization assay in CRTH2-HEK293 cells
CRTH2-HEK cells were transiently transfected to co-express a
chimeric Gaqi5 protein [38,39] engineered to funnel signalling of
Gi-sensitive receptors to the Gq signalling pathway using the
calcium phosphate precipitation method as described previously
[37]. 24 h after transfection cells were detached and replated into
96-well plates at a density of 80,000 cells per well. After 24 h cells
were loaded with the Calcium 4 assay kit (Molecular Devices, CA,
USA) and incubated for 30 min prior to challenge with PGH1,
PGH2 or PGD2, respectively. Fluorescence output was measured
in a NOVOstarH microplate reader with a built-in pipettor (BMG
LabTech, Offenburg, Germany). Detection of fluorescence was
initiated by injecting 20 ml of the respective agonist solution
sequentially into separate wells.
Human peripheral blood eosinophil purification
Blood was taken from healthy non-atopic volunteers according
to a protocol approved by the Institutional Review Board of the
Medical University of Graz and written informed consent was
obtained from donors. Polymorphonuclear leukocytes (PMNL,
including neutrophils and eosinophils) were prepared by dextran
sedimentation of erythrocytes and by further centrifugation on
Histopaque gradients. Eosinophils were purified from the PMNLs
using negative magnetic selection with an antibody cocktail
(CD2, CD14, CD16, CD19, CD56, and glycophorin A) and
colloidal magnetic particles (StemCell Technologies, Vancouver,
Canada) [40].
Calcium ion mobilization assay in human eosinophils
Intracellular free Ca
2+ levels in eosinophils were recorded by
flow cytometry as described previously [41]. Polymorphonuclear
leukocytes were incubated with 2 mM of the acetoxymethyl ester of
the Ca
2+ sensitive dye Fluo-3 and 0.02% pluronic F-127 for
60 minutes at room temperature. Cells were then stained with PE-
conjugated anti-CD16 antibody in order to identify eosinophils as
CD16-negative cells. Changes in intracellular Ca
2+ levels were
detected as the increase in fluorescence in the FL1-channel by flow
cytometry.
Internalization assay in CRTH2-HEK293 cells
CRTH2-HEK cells were grown to ,80% confluence on glass
coverslips pretreated with 1% gelatine. Cells were incubated with
anti-FLAGH M1 antibody (1:1,000) for 30 min at 37uC, then
treated with either DMSO (0.1%) or 10 mM TM30089 for
15 minutes, followed by a 30 min exposure to 1 mM PGD2,1mM
PGH1,o r1 0mM TM30089. Cells were then rinsed once in PBS
and fixed with 4% formaldehyde in phosphate-buffered saline.
Following three washes in TBSC (137 mM NaCl, 25 mM Tris-
base, 3 mM KCl, 1 mM CaCl2), the cells were permeabilized in
blotto (3% milk, 0.1% Triton X-100, 50 mM Tris-HCl, pH 7.4),
stained with Alexa Fluor 488-conjugated goat anti-mouse IgG2b
antibody (1:500, 20 min), washed three times in TBSC, and
mounted on glass microslides using Vectashield mounting
medium. Confocal images were recorded using a Zeiss LSM 510
Meta laser scanning microscope.
Eosinophil shape change assay
Eosinophil shape change was measured by an adaptation of a
method originally developed by Sabroe and coworkers [42]. Ethics
Statement. - The study was approved by National Health Service
Oxfordshire Local Research Ethics Committee and written
informed consent was obtained from donors. Heparinised blood
was collected from healthy volunteers of unknown atopic status
and incubated with red blood cell lysis buffer for 5 min at room
temperature (300 ml of lysis buffer was used for every 100 mlo f
blood) followed by centrifugation at 3006g for 5 min. The
supernatant was removed and leukocytes were resuspended
in 50 ml PBS/2 mM EDTA. Cells were washed twice by
centrifugation at 3006g for 5 min. Leukocytes were resuspended
in RPMI/10% FCS. Fifty microliters of cells were added to a 96-
well microtitre plate, containing 50 ml of test compounds. The
plate was then incubated for 30 min at 37uC, 5% CO2.
Subsequently, the plate was transferred to ice and the cell shape
was fixed by addition of 150 ml cytofix buffer. Cell morphology
was analysed using FACSArray. Eosinophils were gated based on
their autofluorescence and 60,000 events were counted per
sample.
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cells
Human pulmonary microvascular endothelial cells (HMVEC-L)
cryopreserved in tertiary cultures were obtained from Lonza
(Verviers, Belgium) and were maintained in EGM-2 MV Bullet kit
medium (Lonza) supplemented with 5% FCS. 1% gelatine coating
was applied to all culture surfaces to subserve endothelial cell
attachment and growth. The medium was substituted every 2 days
and cells were passaged upon 90% confluence (5–6 days); the cells
were used maximally until passage 10 [43].
Eosinophil adhesion to endothelial cells under flow
conditions
Human pulmonary microvascular endothelial cells (4.3610
5/
substrate) were grown on 1% gelatin-coated VenaEC biochips
(Cellix, Dublin, Ireland). After reaching confluence the endothelial
monolayers were superfused with 100 ml suspensions of 3610
6/ml
eosinophils at 0.5 dyne/cm
2 for 5 min at 37uC in the OKOLAB
H201-T1 heated cage. Eosinophils were pretreated with 10 mM
TM30089 (CRTH2 antagonist) or vehicle in endothelial medium
for 10 min at room temperature followed by treatments with
1 mM PGH1, 30 nM PGD2 or vehicle for 10 min at 37uC prior
the flow experiment. Cell adhesion was recorded by phase contrast
on a Zeiss Axiovert 40 CFL microscope and a Zeiss A-Plan 106/
0.25 Ph1 lens, using Hamamatsu ORCA-03G digital camera and
Cellix VenaFlux software. DucoCell analysis software (Cellix,
Dublin) was applied for computerized image analysis where
adherent eosinophils were quantified on every single image
[40,44].
Culture of human CRTH2
+CD4
+ Th2 cells
Human CRTH2
+CD4
+Th2 cells were prepared using a
modified method described previously [45]. The study was
approved by National Health Service Oxfordshire Local Research
Ethics Committee and written informed consent was obtained
from donors. Briefly, peripheral blood mononuclear cells were
collected from healthy blood donors with unknown atopic status
(National Blood Service, Bristol, UK). Cells were isolated from
buffy coats by Ficoll Hypaque (Amersham Biosciences) density
gradient centrifugation, followed by CD4 cell purification using
MACS CD4 T cell isolation kit II (Miltenyi Biotec, Surrey, UK).
After 7 days of culture in X-VIVO 5 medium (Lonza, Basel,
Switzerland) containing 10% human serum, 50 U/ml IL-2, and
100 ng/ml IL-4, CRTH2
+ cells were isolated from the CD4
cultures by positive selection using an anti-human CRTH2
microbead kit. The harvested CD4
+ CRTH2
+ cells were treated
as Th2 cells and were further amplified by stimulation with a T
cell activation/expansion kit (Miltenyi Biotec, Surrey, UK) and
grown in X-VIVO 15 medium containing 10% human serum and
50 U/ml IL-2 before use.
Calcium ion mobilization assay in human Th2 cells
Human Th2 cells were washed once with Hank’s Balanced Salt
Solution (HBSS) and re-suspended in a FLIPR Calcium 5 loading
buffer (Molecular Devices, CA, USA). The cells were aliquoted at
2610
5 cells/200 ml/well to a 96-well polylysine-coated black wall
clear bottom plate and incubated for 60 min (37uC, 5% CO2)
followed by incubation at room temperature for further 10 min
and subsequently centrifuged at 600 rpm with brake off for 5 min.
The changes in fluorescence after compound loading were
measured by using a FlexStation (Molecular Devices, CA, USA)
with run time 75 s at lex=485 nm and lem=525 nm.
Chemotaxis assays
For measurement of chemotaxis, Th2 cells were resuspended in
X-VIVO 15 medium at 2610
6 cells/ml. The cell suspension
(25 ml) and test samples (29 ml) prepared in X-VIVO 15 were
applied to the upper and lower chambers of a 5-mm pore-sized 96-
well ChemoTx plate (Neuro Probe, MD, USA). After 60 min
incubation at 37uC, any cells remaining on top of the filter were
wiped off and the plates were centrifuged at 3006g for 2 min to
collect the cells on the underside of the filters. Cells were
quantified by fluorescence activated cell sorting (FACS) with the
FACSArray system (BD Biosiences, Oxford, UK). Background cell
migration was determined by measuring the response to media
alone.
Calculations and Data Analysis
Calcium ion mobilization data in CRTH2-HEK cells are (i)
solvent corrected and (ii) corrected for CRTH2-independent
background responses as defined by the presence of the CRTH2-
specific antagonist TM30089 (10 mM). All optical DMR record-
ings are (i) baseline corrected i.e., compound-induced wavelength
shifts were corrected for signals obtained by addition of a
compound-free solvent control and (ii) corrected for non-
CRTH2-dependent background responses obtained upon com-
pound addition into native HEK293 cells. Quantification of DMR
signals was performed by calculation of the area under the curve
(AUC) between 0 and 800 s. EC50 values were obtained by
nonlinear regression analysis using Prism 4.02 (Graph Pad, San
Diego, CA, USA). Statistical analysis was performed by two way
analysis of variance (ANOVA) with Bonferroni’s multiple
comparison post-hoc testing using PrismH 4.02. P values were
considered as significant (*) if p,0.05, as very significant (**) if
p,0.01 and as extremely significant (***) if p,0.001.
Results
To determine the ability of the DGLA-derived 1-series of
prostaglandins (PGs) to stimulate CRTH2, HEK293 cells stably
expressing CRTH2 (CRTH2-HEK cells) were treated with the
various PGs and functional CRTH2 activity was monitored with
an optical biosensor which captures receptor activation as dynamic
mass redistribution (DMR) response [34,35]. DMR assays allow
for non-invasive, real-time recording of CRTH2 function
immediately after ligand exposure. The known CRTH2 agonists
PGD2 and PGH2 were included for comparison and reference
purposes (chemical structures of all tested PGs are depicted in
Table S1). PGH1 and PGD1, but not DGLA or any other 1-series
PG, were capable of inducing CRTH2-mediated DMR with at
least equal efficacy as PGD2 and PGH2 (Figure 1A–E). DMR was
concentration-dependent and the potency of PGH1 was compa-
rable to that of PGH2, although both PG precursors were less
potent than PGD2 (Figure 1F). Importantly, PGH1 displayed no
sign of decomposition during the DMR assay period (Figure S2).
PGH1-activation of CRTH2 was also confirmed using Ca
2+
mobilization assays in CRTH2-HEK cells (Figure 2A–D) and in
primary human eosinophils that endogenously express CRTH2
(Figure 2E) [1–8]. These assays provided another measure of
receptor activity within seconds after agonist exposure and
therefore minimized the possibility of PGH1 modification during
the assay period.
Most G protein coupled receptor (GPCR) agonists promote
receptor internalization following activation [46,47]. To corrob-
orate our findings in yet another independent assay, PGH1 was
tested for its ability to internalize CRTH2 using an ‘antibody
feeding’ approach. Antibody feeding is a powerful technique that
PGH1 Activation of CRTH2
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trafficking [48–50]. Living CRTH2-HEK293 transfectants engi-
neered to express an extracellular FLAG-epitope tag were exposed
to an anti-FLAG antibody under non-permeabilizing conditions
such that only receptors at the surface membrane would be
labelled during exposure to the antibody. Under these conditions,
clear surface staining was observed for CRTH2-HEK cells but not
for control HEK cells (not shown). To assess receptor internali-
zation, CRTH2-HEK cells were first incubated with the anti-
FLAG antibody, followed by stimulation with vehicle control
(Figure 3A), PGH1 (Figure 3B) or PGD2 (Figure 3C)a sa
positive control. After fixation, the cells were permeabilized and
the distribution of the anti-FLAG antibody-labeled receptors was
detected with an Alexa-Fluor 488-labeled secondary antibody.
Compared with vehicle-treated cells (Figure 3A), CRTH2
staining appeared at high density in intracellular vesicles upon
PGH1 exposure, indicating that this ligand stimulated CRTH2
internalization, as did PGD2 (compare Figure 3B and C). The
specificity of PGH1-CRTH2 interaction was further confirmed by
using a selective CRTH2 antagonist (TM30089) [36], which
abolished both PGH1 and PGD2-mediated CRTH2 internaliza-
tion (Figure 3E and F) but was without effect when applied alone
(Figure 3D).
Given the predominant expression of CRTH2 in leukocytes
such as eosinophils and Th2 cells, we investigated whether PGH1
acting through CRTH2 could mediate chemotactic activation of
these cells. PGH1 was competent to induce shape change of
human eosinophils and displays an efficacy comparable to that of
PGH2, although both PGH derivatives demonstrated reduced
efficacy compared to PGD2 (Figure 4A–C). The selective
CRTH2 antagonist TM30089 inhibited the chemotactic activa-
tion of eosinophils, suggesting that this effect is mediated via
CRTH2 (Figure 4A–C). Since activated eosinophils are thought
to contribute to allergic inflammation by adhesion to the
endothelium followed by extravasation, we examined whether
PGH1 was able to modulate eosinophil-endothelial cell interaction
under physiological flow conditions. To this end endothelial
monolayers were grown to confluence on Cellix Vena EC biochip
substrates for two days. Confluent endothelial monolayers were
then superfused with purified eosinophils treated with vehicle,
PGH1 or PGD2 as a reference and images were recorded for
5 min. PGH1 treatment of eosinophils significantly enhanced their
adhesion to endothelial cells as did PGD2, and both agonists were
ineffective in the presence of TM30089 (Figure 5A–G). Hence,
PGH1 promotes eosinophil-endothelial cell adhesion via activation
of CRTH2. Of note, PGH1-induced eosinophil adhesion to the
endothelial layer is comparable to that induced by the chemokine
eotaxin [40], suggesting that PGH1 does not represent an
incomplete activator.
Agonist-induced elevation of intracellular Ca
2+ is a key event for
a variety of cellular processes in immune cells, and both PGD2 and
the CRTH2 agonist indomethacin are known to be potent
inducers of Ca
2+ flux in Th2 cells [1,51]. Whether H
prostaglandins are also endowed with the ability to mobilize
Ca
2+ from intracellular stores in these cells has not been examined
yet. Indeed, PGH1 and PGH2, as well as the reference agonist
PGD2, induced robust and concentration-dependent Ca
2+ re-
sponses in human Th2 cells in a CRTH2-dependent manner
(Figure 6A–C). Ca
2+ responses peaked at ,50–60 s after
compound addition (not shown) and provide further support for
Figure 1. Prostaglandin H1 (PGH1) fully activates CRTH2 in living CRTH2-HEK cell transfectants. A–E, abilities of PGH1, selected
prostaglandins, and the PGH1 precursor dihomo-c-linolenic acid (DGLA) to stimulate CRTH2 signaling using dynamic mass redistribution (DMR)
technology. Cells were challenged with increasing concentrations of the indicated ligands and DMR was recorded as a measure of receptor activity
(representative optical traces). F, transformation of optical traces (A–E) into concentration effect curves. Molar log EC50 values were PGH1:
26.3760.12; PGH2: 27.0960.08; PGD1: 26.9260.16; PGD2: 27.9560.09 (mean values 6 SEM, n=3).
doi:10.1371/journal.pone.0033329.g001
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responsible for the observed CRTH2 activation in human Th2
cells. In line with this notion, PGH1 was also competent to induce
migration of Th2 cells in the absence but not in the presence of
TM30089, as was also observed for PGH2 (Figure 6D–F). The
hematopoietic PGD synthase inhibitor HQL79 did not prevent
the pro-migratory effect of PGH1 ruling out that this response is
due to conversion to PGD1 (Figure S3). As in the case of
eosinophils, the efficacy of both PGH1 and PGH2 was lower than
that of PGD2 in activating Th2 cells.
Discussion
Prostaglandins can be produced from three different precursors,
dihomo-c-linolenic acid (DGLA), arachidonic acid (AA), and
eicosapentaenoic acid (EPA), and the precursor determines which
type of prostanoid is made, series 1, 2, or 3, respectively [52,53].
The 2-series prostanoids are the biologically most active and
abundant ones, and are commonly referred to as lipid mediators of
inflammation [54,55,29]. In fact, there is substantial evidence to
suggest that overproduction of AA-derived eicosanoids may play a
detrimental role in a variety of inflammatory disorders, which is
also reflected by the fact that COX-inhibitors are effective anti-
inflammatory agents and the most common medication taken
worldwide for the treatment of inflammation and inflammatory
pain [56–58,55,59–61]. In contrast, eicosanoids derived from
DGLA such as PGE1 or PGA1 are often viewed as ligands
possessing anti-inflammatory properties [22,62,25,27], and conse-
quently, dietary supplementation of c-linolenic acid to increase the
level of DGLA - at the expense of AA-derived metabolites – has
been proposed to improve clinical symptoms of inflammatory
disorders [33]. So far, 1-series PGs have received rather limited
attention which may relate, at least in part, to the inability of
traditional ELISA methods to distinguish between series 1 and 2
([32] and references therein). A very recent study, however, based
on liquid chromatography-tandem mass spectrometry, identified
prominent production of 1-series PGs in the supernatant of mouse
peritoneal macrophages cultured in the presence of DGLA, a
finding that is clearly suggestive of in vivo production.
Herein, we applied a non-invasive, label-free biosensor
technology based on dynamic mass redistribution of cellular
constituents to examine the ‘‘anti-inflammatory’’ 1-series of
prostaglandins including their precursors DGLA and PGH1 for
potential biological activity on the pro-inflammatory receptor
CRTH2. We demonstrate for the first time that PGH1 and PGD1,
but not PGA1, PGE1 or PGF1a, are functional agonists of
CRTH2. We also provide evidence that CRTH2 activation by
PGH1 can be detected in the receptor’s native environment since
PGH1 is capable of stimulating chemotactic activation of human
eosinophils, and triggers their adhesion to endothelial cells under
physiological flow conditions. PGH1 also positively regulates
Figure 2. Prostaglandin H1 (PGH1) stimulates Ca
2+ mobilization from intracellular stores in CRTH2 transfectants and primary
human eosinophils. A–D: HEK293 cells stably expressing CRTH2 (CRTH2-HEK) were transiently transfected with a chimeric Gaqi5 protein to
channel the Gi-sensitive CRTH2 receptor to mobilization of intracellular Ca
2+. Cells were loaded with a Ca
2+ fluorophore and CRTH2-specific Ca
2+
traces were recorded over time upon challenge with the indicated agonists (A: PGD2, B: PGH1, C: PGH2). A–C: representative data (mean + SEM of
triplicate determinations. D: Maximum responses of all experiments were normalized to Ca
2+ flux induced by 1 mM PGD2 (mean + SEM, n=3). E: PGH1
induces Ca
2+ mobilization in human eosinophils via CRTH2. Intracellular free Ca
2+ levels were quantified by flow cytometry as described in the
methods section. The level of Ca
2+ mobilization in response to vehicle without agonist was set to 100%. Ca
2+ mobilization upon addition of PGH1,
PGH2, and PGD2 is inhibited in the presence of 1 mM of the CRTH2 specific antagonist TM30089. Data are presented as the mean + SEM from 5
experiments conducted in triplicate, each experiment involving eosinophils from a separate donor.
doi:10.1371/journal.pone.0033329.g002
PGH1 Activation of CRTH2
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to inhibition by a CRTH2 specific antagonist.
Compared to PGD2, PGH1 acted as full agonist only in DMR
assays on recombinant cells, but in all other functional readouts
including those in primary eosinophils and Th2 cells, respectively,
PGH1 behaved as a partial agonist. These data imply that PGH1
intrinsic activity may depend on both the assay system under study
and the receptor density which is likely to be lower in cells
expressing the receptor in its native environment. Nonetheless,
these data clearly suggest that both eosinophils and Th2 cells can
be activated by PGH1 in the absence of generation of endogenous
PGD2. Whereas this study mainly focused on signal generation by
the respective PGs, future studies may intend to discriminate PGH1
from other CRTH2 agonists by its ability to terminate signaling.
PGH1, for example – unlike PGH2 – does not appear to be com-
petent to switch off its own signaling at high agonist concentrations
when migration of Th2 cells is the captured cellular event (compare
Figure 6E with F). It will be interesting to unravel whether the
closely related H PGs differ in their abilities to desensitize cellular
responses by for example recruitment of b-arrestin proteins or
activation of second messenger-dependent kinases.
CRTH2 is a remarkably promiscuous receptor, stimulated by
PGD2 and several of its metabolites such as 13,14-dihydro-
15-keto-PGD2, D
12-PGD2, PGJ2, 15-deoxy-D
12,14-PGJ2, and
Figure 3. PGH1 promotes internalization of CRTH2. CRTH2-HEK cells were incubated with the M1 antibody recognizing the FLAG epitope tag
fused in frame to the amino-terminus of CRTH2. Cells were then treated with either solvent control (A), 1 mM PGH1 (B)o r1mM PGD2 (C) in the
absence (A–C) or presence (D–F) of the CRTH2 antagonist TM30089 (10 mM). All ligand-stimulations were performed for 30 min at 37uC. Following
stimulation, cells were fixed, permeabilized and immunostained with a fluorescent secondary antibody and imaged by confocal microscopy.
Experiments were performed three times, and the shown images are representative of cell populations. Scale bars, 10 mm.
doi:10.1371/journal.pone.0033329.g003
Figure 4. PGH1 activates human eosinophils via CRTH2. Human eosinophils were treated with the indicated concentrations of PGD2, PGH1,
and PGH2, respectively, and chemotactic activation was measured in eosinophil shape change assays. Eosinophil shape change is inhibited in the
presence of 1 mM of the CRTH2-specific antagonist TM30089. Note: rank order of PG potency matches well with the results obtained in CRTH2-HEK
transfectants using DMR assays (compare with Figure 1F). Results are expressed as the mean 6 SEM of 3 experiments conducted in triplicate with a
separate donor used in each experiment. Statistical analysis was performed for vehicle vs. TM30089 treated cells and is indicated as (**) for p,0.01
and as (***) for p,0.001.
doi:10.1371/journal.pone.0033329.g004
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12-PGJ2. All of these PGD2-derived ligands arise from the
primary COX product PGH2 through isomerisation by two
specific cytosolic enzymes: lipocalin-type PGD synthase (PGDS)
and hematopoietic PGDS [63–65]. Accordingly, inhibition of
PGDS is being considered as an opportune therapeutic strategy to
treat inflammatory disorders [66–69]. More recently, however,
additional lipid mediators generated from arachidonic acid
independently of PGDS have been identified. Among those are
PGF2a [20], the thromboxane A2 metabolite 11-dehydro-throm-
boxane B2 [21] and PGH2, the precursor for all 2-series
prostaglandins [70]. These data have strong implications
for CRTH2 signaling in the absence of PGD2 production.
Discovery of PGH1 as a functional agonist of CRTH2 is
remarkable for two reasons: (i) because it is viewed as pre-
cursor for PGs with mainly anti-inflammatory properties such
as PGA1 and PGE1 and (ii) because it is yet another lipid
mediator triggering CRTH2 activation independent of PGDS.
Whereas our data reinforce the potential importance of CRTH2
signaling in inflammatory diseases, they also raise the possibility
that efficient suppression of inflammation may require pharma-
Figure 5. PGH1 induces eosinophil adhesion to human pulmonary microvascular endothelial cells under flow conditions. Eosinophils
were pre-incubated with vehicle (A–C)o r1 0mM CRTH2-specific antagonist TM30089 (D–F) for 10 min at room temperature followed by treatment
with vehicle (A, D), 1 mM PGH1 (B, E) or 30 nM PGD2 (C, F) for 10 min at 37uC. Eosinophils were then superfused over human pulmonary
microvascular endothelial cells grown on VenaEC biochips (Cellix, Dublin) for 5 min at 37uC. Representative images were taken 5 min after start of the
superfusion (A–F). G: averaged data from A–F, quantified by computerized image analysis. Data are shown as mean + SEM of 4 experiments.
*P,0.05 PGD2 versus TM30089+PGD2 and PGH1 versus TM30089+PGH1.
doi:10.1371/journal.pone.0033329.g005
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activity.
As CRTH2 is activated by the 2-series PGs containing D, J, and
F-rings, but not A or E-rings [17], it is of interest to determine
whether the same structural requirements are also valid for the 1-
series of PGs. Interestingly, only PGD1 - but not PGA1, PGE1, and
PGF1a - were found to activate CRTH2. These data suggest that
CRTH2 bioactivity is not exclusively governed by the ring
systems, but also by the number of double bonds, since PGF2a and
PGF1a share identical rings, but differ only in saturation of their
carbon chain.
Anti-inflammatory effects of 1-series PGs, in particular PGA1
and PGE1 have been repeatedly demonstrated in vivo and in vitro in
diverse cell types and animal models [22,23,27,71]. PGA1, for
example, has been shown to limit inflammatory responses in
activated monocytes/macrophages via induction of anti-inflam-
matory cytokine IL-10 expression [71] and to suppress NFkappaB
activation which in turn is essential for COX-2 gene expression
[27]. PGE1, on the other hand, appears to possess anti-
inflammatory properties which differ from arachidonic-acid-
derived PGE2 and which favourably affect a variety of inflamma-
tory conditions: PGE1 alleviates inflammation in rat adjuvant
arthritis model [22] and in a mouse lupus model [24], suppresses
immune complex vasculitis [23], inhibits collagenase activity [62]
and ameliorates inflammatory skin diseases [72]. In this context it
is noteworthy that PGH1, the precursor for these two anti-
inflammatory PGs, is a potent and efficacious activator of the pro-
inflammatory receptor CRTH2. Generation of PGH1 requires
cyclo-oxygenases, but not PG synthases, suggesting that generation
of this CRTH2 ligand is not restricted to cells that also co-express
PGD synthases. Although the exact physiological concentrations of
H prostaglandins in the extracellular space at the site of
inflammation may be difficult to determine, there is evidence that
H prostaglandins do not only serve as intracellular substrates for
PG synthases, but may also be secreted from cells in an
untransformed manner [73–78]. Hence, the results presented
herein not only have identified PGH1 as novel CRTH2 ligand;
they also at least in part provide a proof of principle that PGH1
may be competent to promote allergic inflammation via
stimulation of CRTH2. Our findings may be particularly relevant
when fatty acid composition of cell membrane phospholipids, and
hence potential eicosanoid formation, are intended to be altered
with diets enriched in c-linolenic acid or DGLA to foster pro-
duction of putative anti-inflammatory eicosanoids. Indeed, DGLA
content in serum phospholipids has been found to negatively
influence lung function parameters in asthmatic subjects [79]. A
positive association between DGLA plasma levels and the
occurrence of asthma was also found in young adults [80]. Although
the precise mechanisms underlying these clinical observations have
not been elucidated, it is tempting to speculate that CRTH2-
activation by PGH1 may also contribute to the clinical phenotype.
Taken together, our results identify PGH1 as potent and
efficacious activator of the pro-inflammatory receptor CRTH2
and strengthen the role of this receptor as an important player in
allergic inflammation, and hence attractive therapeutic target for
the treatment thereof.
Figure 6. PGH1 activates human Th2 cells via CRTH2. Induction of Ca
2+ mobilization (A–C) and cell migration (D–F) in human Th2 cells in
response to the indicated concentrations of PGD2, PGH1, and PGH2, respectively. The level of cell migration in response to medium without agonist
was set to 1 fold. Both Ca
2+ mobilization and cell migration are inhibited in the presence of 1 mM of the CRTH2 specific antagonist TM30089. Pooled
data is expressed as the mean 6 SEM from 3 experiments conducted in duplicate, each experiment involving Th2 cells from a separate donor.
Statistical analysis was performed for vehicle vs. TM30089 treated cells and is indicated as (*) for p,0.05, as (**) for p,0.01 and as (***) for p,0.001.
doi:10.1371/journal.pone.0033329.g006
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Figure S1 Pathways of eicosanoid production and their
interaction with cellular effector proteins. Dihomo-c-
linolenic acid (DGLA) and arachidonic acid (AA) are converted
to the indicated prostaglandins (PG) and thromboxanes (TX).
Cyclo-oxygenase enzymes 1 and 2 (COX-1/2) convert the
precursors DGLA and AA to PGH1 and PGH2, respectively,
which are acted upon by specific prostaglandin and thromboxane
synthases to either yield the 1-series or the 2-series of eicosanoids.
2-series PGs known to display relevant affinity to CRTH2 are
indicated in green. 1-series PGs with relevant activity on CRTH2
are indicated in blue.
(TIF)
Figure S2 Biosensor fingerprints indicate that PGH1
does not decompose during the real-time functional
DMR assay. Given the reported instability of PGH1,w e
examined the possibility that the ligand might degrade during
the assay period giving rise to its isomerization products PGE1
(inactive at CRTH2) and PGD1 (active at CRTH2). To this end,
optical CRTH2 traces were recorded in CRTH2-HEK cells after
adding PGH1 which was (A) freshly prepared or (B) pre-incubated
in an aqueous solution on CRTH2-HEK cells at a temperature of
28uC for 60 min: DMR traces (A and B) are virtually
superimposable. (C) Decomposition of PGH1 can be excluded
since PGD1 induces optical traces distinct in shape from those
triggered by PGH1, and also, PGE1 does not display any
bioactivity on CRTH2 (see Figure 1F); hence PGH1 is not
biotransformed by the cells during the course of the DMR
experiments. PGH1 was applied at 3 mM and PGD1 at 1 mM final
concentration. Shown are representative traces + SEM of at least
three independent experiments performed in triplicates.
(TIF)
Figure S3 Inhibition of PGD synthase does not alter the
ability of PGH1 to mediate chemotaxis of Th2 cells.
Migration of human Th2 cells in response to various concentra-
tions of PGH1 in the absence or presence of 10 mM HQL-79 was
measured as described in the methods section. Data are expressed
as mean 6 SEM of 3 independent experiments. The level of cell
migration in response to medium without PGH1 in each
experiment was set to 1 fold.
(TIF)
Table S1 Chemical structures of eicosanoids and the
CRTH2 antagonist TM30089.
(TIF)
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